Use of Napsin-A, TTF-1, ER, GCDFP-15, GATA-3 and GATA-3 Markers to Differentiate Breast Metastasis from Lung Adenocarcinoma
Student Research in Translational Medicine,
Vol. 5 (2023),
30 December 2023
https://doi.org/10.22037/srtm.v5.38235
Abstract
Background and Aim: Breast carcinomas with metastasis to lungs and primary lung adenocarcinomas have significant overlap. This study aimed to investigate the differential expression of a panel of IHC markers in primary lung adenocarcinomas and invasive ductal carcinomas (IDC) of the breast.
Methods: In this cross sectional study, total of 50 specimens including 25 primary lung adenocarcinomas and 25 invasive ductal carcinomas of the breast were collected from Masih Daneshvari and Shohada-e-Tajrish hospitals. After all of the cases were stained with hematoxylin - and - eosin, the histologic diagnosis and grading of the slides were reviewed and reported by experienced pathologists based on standard classifications. The patients’ medical records were reviewed for demographic data, clinical information and histopathologic reports.
Results: The median age of the patients with lung adenocarcinoma and IDC was 59 (32-78) and 50 (35-74) years, respectively. In this study, regarding lung adenocarcinomas, the most common type was acinar (56%), followed by solid (20%), mucinous (16%), lepidic (4%), and colloid (4%). Immunohistochemical expression for Napsin-A, TTF-1, ER, GCDFP-15, and GATA-3 in primary lung adenocarcinomas and invasive ductal carcinomas of the breast were different.
Conclusion: Napsin-A, TTF-1, ER, GCDFP-15, GATA-3 and GATA-3 Markers can differentiate the breast cancer from lung adenocarcinoma. Napsin-A and TTF1 only present in lung adenocarcinoma.
- GATA-3, Lung adenocarcinoma, Breast cancer, Differentiation, Metastasis
How to Cite
References
Jung HK, Park S, Kim NW, Lee JE, Kim Z, Han SW, et al.Development of second primary cancer in Korean breast cancer survivors.Annals of surgical treatment and research.2017;93(6):287-92.
Wei J-L, Jiang Y-Z and Shao Z-M.Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.International Journal of Clinical Oncology.2019;24(8):934-40.
Tennis M, Singh B, Hjerpe A, Prochazka M, Czene K, Hall P, et al.Pathological confirmation of primary lung cancer following breast cancer.Lung Cancer.2010;69(1):40-5.
Medeiros B and Allan AL.Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives.International Journal of Molecular Sciences.2019;20(9):2272.
Jin L, Han B, Siegel E, Cui Y, Giuliano A and Cui X.Breast cancer lung metastasis: Molecular biology and therapeutic implications.Cancer Biology & Therapy.2018;19(10):858-68.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA: a cancer journal for clinicians.2018;68(6):394-424.
Yang M and Nonaka D.A study of immunohistochemical differential expression in pulmonary and mammary carcinomas.Modern Pathology.2010;23(5):654-61.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl j Med.2012;366:883-92.
Meng X, Song S, Jiang Z-F, Sun B, Wang T, Zhang S, et al.Receptor conversion in metastatic breast cancer: a prognosticator of survival.Oncotarget.2016;7(44):71887.
Clark BZ, Beriwal S, Dabbs DJ and Bhargava R.Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7–positive carcinomas.American journal of clinical pathology.2014;142(1):64-71.
Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, et al.GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.Human pathology.2016;47(1):26-31.
Selves J, Long-Mira E, Mathieu M-C, Rochaix P and Ilié M.Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site.Cancers.2018;10(4):108.
Tavassoli FA.Pathology and genetics of tumours of the breast and female genital organs.World Hhealth Organization Classification of Tumours.2003.
Pradhan D, Amin M, Hooda S, Dhir R, Bastacky S and Parwani AV.Utility of the laminin immunohistochemical stain in distinguishing invasive from noninvasive urothelial carcinoma.Journal of Cancer Research and Therapeutics.2017;13(6):947.
Guan L, Zhao X, Tang L, Chen J, Zhao J, Guo M, et al.Thyroid transcription Factor-1: structure, expression, function and its relationship with disease.BioMed Research International.2021;2021.
El-Maqsoud NMRA, Tawfiek ER, Abdelmeged A, Rahman MFA and Moustafa AAE.The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.Tumor Biology.2016;37(3):3123-34.
Su Y-C, Hsu Y-C and Chai C-Y.Role Of TTF-1, CK20, And CK7 Immunohistochemistry for Diagnosis of Primary and Secondary Lung Adenocarcinoma.The Kaohsiung Journal of Medical Sciences.2006;22(1):14-19.
Johansson J and Curstedt T.Synthetic surfactants with SP‐B and SP‐C analogues to enable worldwide treatment of neonatal respiratory distress syndrome and other lung diseases.Journal of internal medicine.2019;285(2):165-86.
Bellizzi AM.An algorithmic immunohistochemical approach to define tumor type and assign site of origin.Advances in anatomic pathology.2020;27(3):114.
Enrico D, Saucedo S and Bravo I.Breast metastasis from primary lung adenocarcinoma in a young woman: A case report and literature review.World journal of clinical oncology.2019;10(7):269.
Lee AHS, Hodi Z, Soomro I, Sovani V, Abbas A, Rakha E, et al.Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies.Histopathology.2020;77(2):303-13.
- Abstract Viewed: 116 times
- PDF Downloaded: 68 times
